Tenax TherapeuticsTENX
13F holders, Q3 2024 (September 30)19holders +8
12new positions
4sold out
$3.46avg. 13F price*
At the end of Q3 2024, 19 institutions reported holding Tenax Therapeutics Inc. (TENX) in their 13F filings, up 8 from Q2 2024. 12 opened new positions and 4 sold out. The largest holders were BVF Inc. ($1.2M), Vivo Capital, LLC ($721K) and Venrock Adviser, LLC ($721K).
- Company
- Tenax Therapeutics Inc.
- CUSIP
- 88032L605
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q2 2024 → Q3 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 12 | $4.2M |
| Exits | 4 | $14K |
All 13F filers, Q2 2024 → Q3 2024: 1,215,653 shares bought and 5,563 shares sold, net +1,210,090 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 19 holders
| BVF Inc. | 0.03% | New | 339,549 | $1.2M |
| Vivo Capital, LLC | 0.06% | New | 208,333 | $721K |
| Venrock Adviser, LLC | 0.04% | New | 208,333 | $721K |
| Velan Capital Investment Management LP | 0.31% | New | 83,333 | $288K |
| Vestal Point Capital, LP | 0.02% | New | 83,333 | $288K |
| Adage Capital Partners Gp, L.L.C. | 0.00% | New | 83,333 | $288K |
| ADAR1 Capital Management, LLC | 0.04% | New | 62,423 | $216K |
| Stonepine Capital Management, LLC | 0.11% | New | 50,000 | $173K |
| Sphera Funds Management LTD. | 0.02% | New | 29,166 | $101K |
| T. Rowe Price Associates Inc. | 0.00% | New | 24,000 | $84K |
| Dimensional Fund Advisors LP | 0.00% | New | 21,006 | $73K |
| Geode Capital Management, LLC | 0.00% | Add +66.6% | 18,390 | $64K |
| Lynx1 Capital Management LP | 0.02% | New | 14,751 | $51K |
| Tower Research Capital LLC (TRC) | 0.00% | Add +76.2% | 1,693 | $6K |
| UBS Group AG | 0.00% | Reduce -54.1% | 688 | $2K |
| BlackRock, Inc. | 0.00% | — | 300 | $1K |
| Morgan Stanley | 0.00% | No change | 260 | $900 |
| Bank of America Corp. | 0.00% | Add +75.0% | 28 | $97 |
| Allworth Financial LP | 0.00% | No change | 1 | $4 |
"% of holder's portfolio" is TENX's weight in each manager's 13F, not the share of Tenax Therapeutics Inc. the manager owns.